Despite Elicera Therapeutics' Pullback, Insiders Still Gained kr616k

Insiders who bought Elicera Therapeutics AB (publ) (STO:ELIC) in the last 12 months may probably not pay attention to the stock's recent 12% drop. Even after accounting for the recent loss, the kr3.49m worth of stock purchased by them is now worth kr4.11m or in other words, their investment continues to give good returns.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Elicera Therapeutics

The Last 12 Months Of Insider Transactions At Elicera Therapeutics

In the last twelve months, the biggest single purchase by an insider was when CEO & Co-Founder Jamal El-Mosleh bought kr3.4m worth of shares at a price of kr1.28 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of kr1.50. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Jamal El-Mosleh bought a total of 2.74m shares over the year at an average price of kr1.27. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Elicera Therapeutics insiders own about kr16m worth of shares. That equates to 31% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Elicera Therapeutics Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. Insiders own shares in Elicera Therapeutics and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, Elicera Therapeutics has 7 warning signs (and 5 which are significant) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.